Matt Henriksen

Yeah.

And then...

For the payers themselves, I mean, for them, they see some benefit of that as well because there's, I mean, maybe, how would I want to put this?

There's less risk involved of having to pay that upfront payment, right?

And so like that, when you see that $3,000 payment and then they switch,

the payers are eating that cost, right?

Very interesting.

And then, you know, kind of then going back to the patients that benefit from this.

I mean, we talked about in the, with the pivotal trial, how sicker patients benefited from it as much as kind of the, you know, patients that are, you know, more into the treatment beforehand.

But, you know, we also talked about the type one and the type two market.

You know, we talked about, you know, roughly the same size, but different

access points for those patients.

The other interesting thing that I've taken from this is that while technically the islet doesn't have a label for the type 2, during your earning calls, you're highlighting how these primary care physicians are still prescribing it to those patients.

And you're mentioning a significant amount of patients, almost up to 30%, if I remember correctly, that of your new patients are actually type 2.

So...

Well, one winded way of asking about how is those, you know, how are those approaches different for the type one patients and the type two patients?

Yeah.

And you know, it's interesting too, because I mean, I believe you guys are considering a type two label, um,

Yeah, I can see the benefits in one way or the other.

On one hand, you're already reaching out to the, not you, but the doctors are already reaching out to those type two patients.